Danaher Corp
DHRNYSEIndustrial Instruments For Measurement, Display, and ControlFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 26, 2026Last filing: 10-Q on Jul 21, 2026Score 12/3027% above fair value
$227.97−4.26 (-1.83%)
Close on Nov 2, 2026Market cap $160.26BP/E 40.5Yield –
Danaher Biotechnology — Biên Adjusted EBITDA by Quarter
Biotechnology — Biên Adjusted EBITDA (%)
Danaher Biotechnology — Biên Adjusted EBITDA: 44.3% in Q3 2026, up 5.0 pts from a year earlier.
Latest, Q3 2026
44.3%
Period ended Sep 30, 2026
Change on a year earlier
+5.0 pts
39.3% in Q3 2025
History
19 quarters
Since Q1 2022
Sources
11
Documents cited below
Where the Q3 2026 figure comes from
Source: Danaher IR — nongaap_2026Q3 ↗
Reported in Danaher Non-GAAP Reconciliations & Supplemental Data (8-K / IR PDF).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Biotechnology — Biên Adjusted EBITDA (%) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 44.3% | +5.0 pts | Danaher IR — nongaap_2026Q3 ↗ |
| Q2 2026 | Jun 30, 2026 | 43.1% | 0.0 pts | Danaher IR — nongaap_2026Q2 ↗ |
| Q1 2026 | Mar 31, 2026 | 45.0% | +1.4 pts | Danaher IR — nongaap_2026Q1 ↗ |
| Q4 2025 | Dec 31, 2025 | 39.8% | -0.8 pts | Danaher IR — nongaap_2025Q4 ↗ |
| Q3 2025 | Sep 30, 2025 | 39.3% | +0.3 pts | Danaher IR — nongaap_2026Q3 ↗ |
| Q2 2025 | Jun 30, 2025 | 43.1% | +1.6 pts | Danaher IR — nongaap_2026Q2 ↗ |
| Q1 2025 | Mar 31, 2025 | 43.6% | +5.2 pts | Danaher IR — nongaap_2026Q1 ↗ |
| Q4 2024 | Dec 31, 2024 | 40.6% | +1.6 pts | Danaher IR — nongaap_2025Q4 ↗ |
| Q3 2024 | Sep 30, 2024 | 39.0% | -1.3 pts | Danaher IR — nongaap_2025Q3 ↗ |
| Q2 2024 | Jun 30, 2024 | 41.5% | +0.2 pts | Danaher IR — nongaap_2025Q2 ↗ |
| Q1 2024 | Mar 31, 2024 | 38.4% | -7.4 pts | Danaher IR — nongaap_2025Q1 ↗ |
| Q4 2023 | Dec 31, 2023 | 39.0% | -3.8 pts | Danaher IR — nongaap_2024Q4 ↗ |
| Q3 2023 | Sep 30, 2023 | 40.3% | -4.9 pts | Danaher IR — nongaap_2024Q3 ↗ |
| Q2 2023 | Jun 30, 2023 | 41.3% | -6.0 pts | Danaher IR — nongaap_2024Q2 ↗ |
| Q1 2023 | Mar 31, 2023 | 45.8% | -2.6 pts | Danaher IR — nongaap_ex_veralto ↗ |
| Q4 2022 | Dec 31, 2022 | 42.8% | – | Danaher IR — nongaap_ex_veralto ↗ |
| Q3 2022 | Sep 30, 2022 | 45.2% | – | Danaher IR — nongaap_ex_veralto ↗ |
| Q2 2022 | Jun 30, 2022 | 47.3% | – | Danaher IR — nongaap_ex_veralto ↗ |
| Q1 2022 | Mar 31, 2022 | 48.4% | – | Danaher IR — nongaap_ex_veralto ↗ |
Cite this data
StockData. (2026). Danaher Biotechnology — Biên Adjusted EBITDA (%), quarterly Q1 2022–Q3 2026 [Data set]. Compiled from Danaher SEC filings and investor materials. https://stockdatahq.com/stocks/dhr/kpis/adj-ebitda-margin-biotech
See every metric in the Danaher KPI table. Data updated Nov 2, 2026.